Balmoral Medical company
Quick facts
Marketed products
- Metronidazole Vaginal Gel 0.75% · Infectious Disease
Metronidazole disrupts bacterial DNA by generating reactive oxygen species and damaging microbial genetic material, thereby killing anaerobic bacteria and protozoa.
Phase 3 pipeline
- Clindamycin Phosphate Lotion 1% · Dermatology
Clindamycin phosphate inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, reducing acne-causing bacteria and inflammation on the skin. - GDC-229 · Oncology
GDC-229 is a small molecule targeting the PI3K pathway. - GDC 268 Lotion · Dermatology
GDC 268 Lotion is a topical corticosteroid used to reduce inflammation and itching. - GDC 695 · Immunology
GDC 695 is a small molecule targeting the PI3K delta (p110δ) subunit. - GDC Vehicle Lotion · Dermatology
GDC Vehicle Lotion is a topical lotion used as a vehicle for drug delivery.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Balmoral Medical company
What are Balmoral Medical company's marketed drugs?
Top marketed products include Metronidazole Vaginal Gel 0.75%.
What is Balmoral Medical company's pipeline?
Balmoral Medical company has 5 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include Clindamycin Phosphate Lotion 1%, GDC-229, GDC 268 Lotion, GDC 695.
Related
- Metronidazole Vaginal Gel 0.75% · Infectious Disease
- Sector hub: All tracked pharma companies